pharming portmanteau farming pharmaceutical refers use genetic engineering insert genes code useful pharmaceuticals host animals plants would otherwise express genes thus creating genetically modified organism pharming also known molecular farming molecular products pharming recombinant proteins metabolic products recombinant proteins commonly produced using bacteria yeast bioreactor pharming offers advantage producer require expensive infrastructure production capacity quickly scaled meet demand greatly reduced first recombinant plantderived protein pdp human serum albumin initially produced transgenic tobacco potato open field growing trials crops began united states taken place every year since united states department agriculture approved planting pharma crops every state testing taken place hawaii nebraska iowa early pharming industry robust proof concept established production many therapeutic proteins including antibodies blood products cytokines growth factors hormones recombinant enzymes human veterinary several pdp products treatment human diseases development nearly biotech companies including recombinant gastric lipase treatment cystic fibrosis antibodies prevention dental caries treatment nonhodgkins however late prodigene ramping production trypsin commercial discovered volunteer plants left prior harvest one gm corn products harvested conventional soybean crop later planted source prodigene fined ordered usda pay million cleanup costs raised furor set pharming field back many companies went bankrupt companies faced difficulties getting permits field trials investors reaction aphis introduced strict regulations pharming field trials us anheuserbusch threatened boycott rice grown missouri plans ventria bioscience grow pharm rice state compromise reached ventria withdrew permit plant missouri due unrelated circumstances industry slowly recovered focusing pharming simple plants grown bioreactors growing gm crops companies academic groups continued openfield trials gm crops produce drugs dow agrosciences received usda approval market vaccine poultry newcastle disease produced plant cell culture first plantproduced vaccine approved milk presently mature system produce recombinant proteins transgenic organisms blood egg white seminal plasma urine theoretically possible systems drawbacks blood instance store high levels stable recombinant proteins biologically active proteins blood may alter health expression milk mammal cow sheep goat common application milk production plentiful purification milk relatively easy hamsters rabbits also used preliminary studies faster breeding one approach technology creation transgenic mammal produce biopharmaceutical milk blood urine animal produced typically using pronuclear microinjection method becomes efficacious use cloning technology create additional offspring carry favorable modified february us fda granted marketing approval first drug produced genetically modified drug called atryn antithrombin protein purified milk genetically modified goats marketing permission granted european medicines agency august indicated mammals typically used food production goats sheep pigs cows modified produce nonfood products practice sometimes called pharming use genetically modified goats approved fda ema produce atryn ie recombinant antithrombin anticoagulant protein products produced turning animals drugmanufacturing machines genetically modifying sometimes termed biopharmaceuticals patentability biopharmaceuticals process manufacture uncertain probably biopharmaceuticals made unpatentable assuming chemically identical preexisting drugs imitate several century united states supreme court decisions hold previously known natural product manufactured artificial means argument made patentability process manufacturing biopharmaceutical however genetically modifying animals produce drug dissimilar previous methods manufacture moreover one supreme court decision seems hold open hand suggested recent supreme court decision mayo v may create problem accordance ruling case may said genes manufacture protein way always mammal produce product genetic modification technology used conventional steps process add nothing laws nature already argument prevailed court process would also ineligible patent protection issue yet decided courts plantmade pharmaceuticals pmps also referred pharming subsector biotechnology industry involves process genetically engineering plants produce certain types therapeutically important proteins associated molecules peptides secondary metabolites proteins molecules harvested used produce arabidopsis often used model organism study gene expression plants actual production may carried maize rice potatoes tobacco flax tobacco highly popular choice organism expression transgenes easily transformed produces abundant tissues survives well vitro advantage rice flax selfpollinating thus gene flow issues see avoided however human error could still result modified crops entering food supply using minor crop safflower tobacco avoids greater political pressures risk food supply involved using staple crops beans rice expression proteins plant cell hairy root cultures also minimizes risk gene transfer higher cost production sterile hybrids may also used bioconfinement transgenic plants although stable lines grain crops sometimes chosen pharming protein products targeted endosperm cereals shown high heat stability characteristic makes appealing target production edible vaccines viral coat proteins stored grains require cold storage way many vaccines currently maintaining temperature controlled supply chain vaccines often difficult delivering vaccines developing commonly plant transformation carried using agrobacterium tumefaciens protein interest often expressed control cauliflower mosaic virus promoter powerful constitutive promoter driving expression localization signals may attached protein interest cause accumulation occur specific subcellular location chloroplasts vacuoles done order improve yields simplify purification protein folds recently inclusion antisense genes expression cassettes shown potential improving plant pharming process researchers japan transformed rice antisense spk gene disrupts starch accumulation rice seeds products would accumulate watery sap easier recently several noncrop plants duckweed lemna minor moss physcomitrella patens shown useful production biopharmaceuticals frugal organisms cultivated bioreactors opposed grown fields secrete transformed proteins growth medium thus substantially reduce burden protein purification preparing recombinant proteins medical addition species engineered cause secretion proteins human patterns glycosylation improvement conventional plant geneexpression biolex therapeutics developed duckweedbased expression platform sold business synthon declared bankruptcy needed additionally israeli company protalix developed method produce therapeutics cultured transgenic carrot tobacco protalix partner pfizer received fda approval market drug taliglucerase alfa elelyso treatment gauchers disease regulation genetic engineering concerns approaches taken governments assess manage risks associated development release genetically modified crops differences regulation gm crops including used pharming countries marked differences occurring usa europe regulation varies given country depending intended use products genetic engineering example crop intended food use generally reviewed authorities responsible food safety controversies around gmos generally several levels including whether making ethical issues concerning intellectual property market dynamics environmental effects gm crops gm crops role industrial agricultural generally also specific controversies around pharming plants carry pathogens might dangerous human health additionally level pharmacologically active proteins proteins plants similar human proteins hand plants still sufficiently closely related animals humans able correctly process configure animal human proteins seeds fruits also provide sterile packaging containers valuable therapeutics guarantee certain storage global demand pharmaceuticals unprecedented levels expanding existing microbial systems although feasible therapeutic products satisfactory option several many proteins interest complex made microbial systems protein proteins currently produced animal cell cultures resulting product often prohibitively expensive many patients reasons science exploring options producing proteins therapeutic pharmaceutical crops could become extremely beneficial developing countries world health organization estimates nearly million people die year vaccine preventable disease mostly africa diseases measles hepatitis lead deaths countries people afford high costs vaccines pharm crops could help solve molecular farming one application genetic engineering concerns unique case genetically modified gm foods concerns focus safety food human consumption response argued genes enhance crop way drought resistance pesticide resistance believed affect food gm foods development fruits designed ripen faster grow larger believed affect humans differently nongm contrast molecular farming intended crops destined food chain produces plants contain physiologically active compounds accumulate plant tissues considerable attention focused therefore restraint caution necessary protect consumer health environmental fact plants used produce drugs alarms activists worry production begins altered plants might find way food supply crosspollinate conventional nongm concerns historical validation prodigene incident starlink incident gmo corn accidentally ended commercial food products activists also concerned power business according canadian food inspection agency recent report says us demand alone biotech pharmaceuticals expanding percent annually reach market value billion pharming expected worth billion globally please note list means exhaustive projects known abandoned